#### Edgar Filing: ARRAY BIOPHARMA INC - Form 4

ARRAY BIO Form 4 October 05, 2	PHARMA INC										
									OMB A	PPROVAL	
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								OMB Number:	3235-0287		
Check this if no long subject to Section 16 Form 4 or Form 5 obligation may conti See Instru	er <b>STATEM</b> 5. Filed purs <sup>15</sup> Section 17(a	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940									
1(b).											
(Print or Type R	esponses)										
1. Name and Address of Reporting Person <u>*</u> KOCH KEVIN			2. Issuer Name <b>and</b> Ticker or Trading Symbol ARRAY BIOPHARMA INC [ARRY]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last)	(First) (M	-			neaction			_X_ Director	10%	Owner	
3200 WALN	3. Date of Earliest Transaction (Month/Day/Year) 10/04/2012					Officer (give title Other (specify below) below) President, CSO					
			4. If Amendment, Date Original Filed(Month/Day/Year)					<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> </ul>			
BOULDER,	CO 80301							Form filed by N Person	fore than One Re	eporting	
(City)	(State) (	Zip)	Table	e I - Non-De	erivative S	ecurit	ies Acq	uired, Disposed of	f, or Beneficial	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution any	Date, if	3. Transactic Code (Instr. 8) Code V	n(A) or Dis (D)	posed	of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect Beneficial	
Common Stock	10/04/2012			А	22,718	A	\$ 0 (1)	774,954	D		
Common Stock								43,286	Ι	Held By Spouse	
Common Stock								99,000	I	Held in trust for children	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form (9-02)

#### Edgar Filing: ARRAY BIOPHARMA INC - Form 4

# displays a currently valid OMB control number.

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	5	Date	Secur	ınt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owna Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## **Reporting Owners**

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
KOCH KEVIN 3200 WALNUT STREET BOULDER, CO 80301	Х		President, CSO					
Signatures								
John R. Moore, attorney-in-fac Person	t for Repo	orting	10/05/2012					
**Signature of Reporting I		Date						

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These fully vested shares were issued as a bonus pursuant to the fiscal 2012 Performance Bonus Program and the Array BioPharma Inc. Amended and Restated Stock Option and Incentive Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.